CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis

CompletedOBSERVATIONAL
Enrollment

41

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Rheumatoid ArthritisPsoriatic Arthritis
Interventions
OTHER

Multi-parametric Flow Cytometry analysis on patients and healthy donors samples

"Collection of venous blood (16 mL) and synovial fluid (when available) samples, for each patient, at inclusion and in the frame of the usual medical follow-up at 3 months and between 6 and 12 months, before the onset of MTX (untreated patients) or during the course of MTX treatment (MTX-treated patients).~Collection of anonymous healthy donors blood samples, age- and sex-matched, obtained from the Etablissement Français du Sang.~Multi-parametric Flow Cytometry analysis was performed on these samples to assess CD73 expression on total memory T cells and within T helper lymphocyte subsets, their cytokine production and AMPase functions. For FoxP3 intracellular staining, cells were treated using the FoxP3 Fixation and Permeabilization kit (Life Technologies), according to manufacturer instructions. Stainings were analyzed on a LSR-Fortessa™ (BD Biosciences) with conserved settings throughout the entire study and data were analyzed using FlowJo™ Software (Tree Star v10.4)."

Trial Locations (1)

69495

Service de Rhumatologie, Centre Hospitalier Lyon-Sud (HCL), Pierre-Bénite

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03953378 - CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis | Biotech Hunter | Biotech Hunter